Cue Biopharma Reports Director/Officer Changes & Corporate Updates
Ticker: CUE · Form: 8-K · Filed: Jun 10, 2025 · CIK: 1645460
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, filing-update
TL;DR
Cue Biopharma's 8-K shows director/officer shakeups and corporate changes as of June 4th.
AI Summary
Cue Biopharma, Inc. filed an 8-K on June 10, 2025, reporting several key events as of June 4, 2025. These include the departure of directors or certain officers, the election of new directors, the appointment of certain officers, and updates to compensatory arrangements. The filing also covers amendments to articles of incorporation or bylaws, changes in fiscal year, and the submission of matters to a vote of security holders. Additionally, it includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate governance and structural changes within Cue Biopharma, which could impact its strategic direction and operational management.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with amendments to corporate documents, can signal shifts in strategy or internal dynamics that may affect the company's future performance.
Key Players & Entities
- Cue Biopharma, Inc. (company) — Registrant
- June 4, 2025 (date) — Earliest event reported
- June 10, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of Incorporation
- 40 Guest Street Boston, Massachusetts 02135 (address) — Principal Executive Offices
FAQ
What specific changes were made regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, but the specific names and details are not provided in this excerpt.
Were there any amendments to Cue Biopharma's articles of incorporation or bylaws?
Yes, the filing explicitly lists 'Amendments to Articles of Incorporation or Bylaws' as an item of information being reported.
Did Cue Biopharma's fiscal year change?
The filing indicates 'Change in Fiscal Year' as one of the reported items, suggesting a potential change.
Were any matters submitted to a vote of security holders?
Yes, the filing states 'Submission of Matters to a Vote of Security Holders' as an item of information being reported.
What is the company's principal executive office address?
The company's principal executive offices are located at 40 Guest Street, Boston, Massachusetts 02135.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 10, 2025 regarding Cue Biopharma, Inc. (CUE).